Recruiting Major Depressive Disorder Studies in Glendale
Study to Assess the Safety and Effectiveness of NMRA-335140-501
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who ...
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant i...
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants ...
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive diso...
Study of ALTO-300 in MDD
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics....
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who ha...
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD)....
About Major Depressive Disorder Clinical Trials in Glendale
Major depressive disorder (MDD) is a severe form of depression characterized by persistent sadness, loss of interest, and impaired daily functioning. Treatment-resistant depression (TRD) affects patients who do not respond to standard therapies. Novel treatments like ketamine, psilocybin, and neuromodulation are being studied.
There are currently 7 major depressive disorder clinical trials recruiting participants in Glendale, CALIFORNIA. These studies are seeking a combined 3,308 participants. Research is being sponsored by Neumora Therapeutics, Inc., Janssen Research & Development, LLC, Xenon Pharmaceuticals Inc. and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Major Depressive Disorder Clinical Trials in Glendale — FAQ
Are there major depressive disorder clinical trials in Glendale?
Yes, there are 7 major depressive disorder clinical trials currently recruiting in Glendale, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Glendale?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Glendale research site will contact you about next steps.
Are clinical trials in Glendale free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Glendale studies also compensate for your time and travel.
What major depressive disorder treatments are being tested?
The 7 active trials in Glendale are testing new therapies including novel drugs, biologics, and treatment approaches for major depressive disorder.
Data updated March 2, 2026 from ClinicalTrials.gov